These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

50 related items for PubMed ID: 3104218

  • 1. Pharmacokinetics and pharmacological properties of two galenical preparations of glibenclamide, HB419 and HB420, in non insulin-dependent (type 2) diabetes.
    Scheen AJ, Jaminet C, Luyckx AS, Lefebvre PJ.
    Int J Clin Pharmacol Ther Toxicol; 1987 Feb; 25(2):70-6. PubMed ID: 3104218
    [Abstract] [Full Text] [Related]

  • 2. In vivo action of glibenclamide in obese subjects with mild type 2 (non-insulin dependent) diabetes.
    Hother-Nielsen O, Schmitz O, Andersen PH, Pedersen O, Beck-Nielsen H.
    Diabetes Res; 1988 Jun; 8(2):63-70. PubMed ID: 3147830
    [Abstract] [Full Text] [Related]

  • 3. Combination of insulin and glibenclamide in the treatment of elderly non-insulin dependent (type 2) diabetic patients.
    Kyllästinen M, Groop L.
    Ann Clin Res; 1985 Jun; 17(3):100-4. PubMed ID: 3931537
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Pharmacodynamics and pharmacokinetics of 2 glibenclamide preparations in type 2 diabetes. Intraindividual double-blind comparison of Euglucon 5 (HB 419) and Euglucon N (HB 420)].
    Haupt E, Putschky F, Zoltobrocki M, Schöffling K.
    Dtsch Med Wochenschr; 1984 Feb 10; 109(6):210-3. PubMed ID: 6421561
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A double-blind comparison of two glibenclamide preparations, HB 419 and HB 420, in maturity-onset (type 2) diabetic patients.
    Arnala I, Uusitupa M.
    Ann Clin Res; 1983 Feb 10; 15 Suppl 37():33-5. PubMed ID: 6433770
    [Abstract] [Full Text] [Related]

  • 9. [Effect of acarbose on postprandial increase in blood glucose. Additive acute effect of once daily administration in insulin treated diabetes].
    Ledermann H, Höxter G.
    Fortschr Med; 1994 Nov 20; 112(32):467-70. PubMed ID: 7821886
    [Abstract] [Full Text] [Related]

  • 10. Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide.
    Yngen M, Ostenson CG, Hjemdahl P, Wallén NH.
    Diabet Med; 2006 Feb 20; 23(2):134-40. PubMed ID: 16433710
    [Abstract] [Full Text] [Related]

  • 11. The effect of improved post-prandial blood glucose control on post-prandial metabolism and markers of vascular risk in people with Type 2 diabetes.
    Gallagher A, Home PD.
    Diabetes Res Clin Pract; 2005 Mar 20; 67(3):196-203. PubMed ID: 15713351
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics and metabolic effects of glibenclamide and glipizide in type 2 diabetics.
    Groop L, Wåhlin-Boll E, Groop PH, Tötterman KJ, Melander A, Tolppanen EM, Fyhrqvist F.
    Eur J Clin Pharmacol; 1985 Mar 20; 28(6):697-704. PubMed ID: 3933984
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Mechanism of action of combined administration of glibenclamide and insulin in type II diabetics with secondary failure of oral treatment].
    Schmidt FH, Klujko J, Kühnle HF, Reiter J.
    Klin Wochenschr; 1986 Oct 15; 64(20):1021-3. PubMed ID: 3097384
    [Abstract] [Full Text] [Related]

  • 16. How does glibenclamide lower plasma glucose concentration in patients with type 2 diabetes?
    Jeng CY, Hollenbeck CB, Wu MS, Chen YD, Reaven GM.
    Diabet Med; 1989 Oct 15; 6(4):303-8. PubMed ID: 2524334
    [Abstract] [Full Text] [Related]

  • 17. Improved diabetic control in insulin-dependent diabetics treated with insulin and glibenclamide.
    Burke BJ, Hartog M, Waterfield MR.
    Acta Endocrinol (Copenh); 1984 Sep 15; 107(1):70-7. PubMed ID: 6435371
    [Abstract] [Full Text] [Related]

  • 18. Glibenclamide steady state plasma levels during concomitant vinpocetine administration in type II diabetic patients.
    Grandt R, Braun W, Schulz HU, Lührmann B, Frercks HJ.
    Arzneimittelforschung; 1989 Nov 15; 39(11):1451-4. PubMed ID: 2515864
    [Abstract] [Full Text] [Related]

  • 19. Glibenclamide pharmacokinetics in acarbose-treated type 2 diabetics.
    Gerard J, Lefebvre PJ, Luyckx AS.
    Eur J Clin Pharmacol; 1984 Nov 15; 27(2):233-6. PubMed ID: 6437842
    [Abstract] [Full Text] [Related]

  • 20. [14C-Glibenclamide concentrations in serum and 14C-glibenclamide urine excretion in diabetic patients with simultaneous determination of blood glucose and insulin (author's transl)].
    Birk W, Schmidt HA, Petrides P.
    Arzneimittelforschung; 1978 Nov 15; 28(2):330-7. PubMed ID: 416832
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.